Baroldi Joseph 4

What Happened

• Joseph Baroldi, EVP & Chief Business Officer of Ionis Pharmaceuticals (IONS), had 10,837 restricted stock units (RSUs) vest and convert into 10,837 shares on 2026-04-15 (reported as a derivative conversion, code M) at no purchase price. On 2026-04-16 he sold 5,619 of those shares in the open market (code S) for a weighted average price of $74.56, generating proceeds of approximately $418,953. The sale was an automatic sale-to-cover tax withholding obligations tied to the RSU vesting.

Key Details

• Transaction dates: RSU conversion 2026-04-15; open-market sale 2026-04-16; Form 4 filed 2026-04-17 (appears timely).
• RSU conversion: 10,837 shares acquired at $0.00 (conversion of vested RSUs).
• Sale: 5,619 shares disposed at a weighted average price of $74.56; reported price range $74.12–$75.01. Footnote indicates the filer can provide per-price breakdown on request.
• Reason for sale: Footnote states the sale was an automatic sale to cover required tax withholding under the company’s 2011 Equity Incentive Plan.
• RSU terms: Each RSU equals one share; RSUs vest in four equal annual installments and are paid in shares or cash per plan (footnotes F4–F5).
• Shares owned after the transactions are not specified in the provided Form 4.

Context

• This was mainly a routine award vesting (not a market purchase) with a partial sale to satisfy tax withholding — a common administrative transaction that doesn’t necessarily signal a change in insider sentiment. The RSU conversion (code M) and subsequent sale-to-cover are standard; no 10b5-1 plan or late filing is indicated in the provided information.